Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BroVID: Effect of Bronchipret on antiviral immune response in mild COVID-19
2021-003237-11Phase 2Completed
- Sponsor
- Fraunhofer-Gesellschaft
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of Bronchipret in coronavirus disease 2019 (COVID-19) and airway morbidity (2 arms), sponsored by Fraunhofer-Gesellschaft. Primary endpoint: Primary immune response blood parameters at day 7. Started Aug 2021; status: completed.
02
Drugs
Bronchipret
03
Conditions
coronavirus disease 2019 (COVID-19)airway morbidity
Beyond the preview
Go deeper on 2021-003237-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003237-11.